| Ballroom C (Washington DC Convention Center) | |||
| Chemotherapy-Induced Peripheral Neuropathy | |||
| More than 1.3 million people will be diagnosed with cancer during 2006. Chemotherapy is an essential component of the armamentarium to cure or control the disease. Although effective, chemotherapy is associated with significant toxicities, particularly peripheral neuropathy. The prevalence of chemotherapy-induced peripheral neuropathy (CIPN) is not clear and the risk factors have not been well delineated. Furthermore, the sensorimotor changes associated with CIPN have not been precisely characterized. For many patients, this adverse effect is devastating, limiting their ability to walk, stand, or perform normal hygiene and other activities of daily living. In some cases, CIPN results in dose reduction or discontinuation, limiting the potentially curative effect of the chemotherapeutic agent. Although treated within cancer centers, clinicians with expertise in pain are often asked to provide consultation. This symposium will provide current findings from the clinical and laboratory settings. Judith Paice will review existing CIPN prevalence data. Videos of patients with CIPN will be used to illustrate the effect of this syndrome on function and quality of life. Patrick Mantyh will describe mechanisms of CIPN derived from a rodent model developed within his laboratory. Gilbert Wong will discuss management options, including clinical trials conducted to prevent and treat this syndrome. | |||
| Moderator: | Judith A. Paice, PhD, RN | ||
| Presenters: | Patrick W. Mantyh, PhD Gilbert Y. Wong, MD | ||
| Chemotherapy-Induced Peripheral Neuropathy Judith A. Paice, PhD, RN | |||
| Chemotherapy-Induced Peripheral Neuropathy-1 Patrick W. Mantyh, PhD | |||
| Chemotherapy-Induced Peripheral Neuropathy-2 Gilbert Y. Wong, MD | |||
[Handout]
Return to the Schedule of Events
See more of Symposia